Research programme: nanopolymer-conjugated anticancer drugs - Rexahn

Drug Profile

Research programme: nanopolymer-conjugated anticancer drugs - Rexahn

Alternative Names: HPMA-docetaxel-folate; HPMA-gemcitabine; Nanopolymer anticancer drugs; RX-21101; RX-21202

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Drug conjugates; Polymers; Pyrimidine nucleosides; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top